About: The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study
Creator	Wu, Xiao Peng, Cheng Chen, Wei Zhou, Min Chen, Li »more»
source	MedRxiv
abstract	Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65109/L vs. 0.76109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.
has issue date	2020-03-23(xsd:dateTime)
bibo:doi	10.1101/2020.03.16.20036145
has license	medrxiv
sha1sum (hex)	3bd918c5102ace400552417aef81dec050636553
schema:url	https://doi.org/10.1101/2020.03.16.20036145
resource representing a document's title	The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study
resource representing a document's body	covid:3bd918c5102ace400552417aef81dec050636553#body_text
is schema:about of	named entity 'donors' named entity 'days' named entity '640' named entity 'plasma' covid:arg/3bd918c5102ace400552417aef81dec050636553 »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software